WO2007012170A1 - A new method and apparatus to attain and maintain target end tidal gas concentrations - Google Patents
A new method and apparatus to attain and maintain target end tidal gas concentrations Download PDFInfo
- Publication number
- WO2007012170A1 WO2007012170A1 PCT/CA2005/001166 CA2005001166W WO2007012170A1 WO 2007012170 A1 WO2007012170 A1 WO 2007012170A1 CA 2005001166 W CA2005001166 W CA 2005001166W WO 2007012170 A1 WO2007012170 A1 WO 2007012170A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gas
- end tidal
- concentration
- concentrations
- levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0051—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes with alarm devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/083—Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
- A61B5/0833—Measuring rate of oxygen consumption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/083—Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
- A61B5/0836—Measuring rate of CO2 production
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0045—Means for re-breathing exhaled gases, e.g. for hyperventilation treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0057—Pumps therefor
- A61M16/0078—Breathing bags
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A61M16/0841—Joints or connectors for sampling
- A61M16/085—Gas sampling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
- A61M2016/0018—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
- A61M2016/0021—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with a proportional output signal, e.g. from a thermistor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
- A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
- A61M2016/0039—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/202—Blood composition characteristics partial carbon oxide pressure, e.g. partial dioxide pressure (P-CO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/43—Composition of exhalation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/43—Composition of exhalation
- A61M2230/432—Composition of exhalation partial CO2 pressure (P-CO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/40—Respiratory characteristics
- A61M2230/43—Composition of exhalation
- A61M2230/435—Composition of exhalation partial O2 pressure (P-O2)
Definitions
- the invention disclosed herein relates to the field of blood gas control, which further relates to a number of fields of medical diagnostics and treatment.
- Changes in end tidal CO 2 and/or O 2 can be used to monitor vascular reactivity in retinal vessels and other vascular beds as detected by various retinal blood flow and other vascular flow sensors.
- changes in end tidal CO 2 and/or O 2 can be used to monitor changes on organ or tissue function by measuring such factors as heart rate variability, skin conductivity s hormone levels, organ temperature, plethysmography and other measurements known to physiologists and others skilled in the art.
- the present invention relates to a method to control the end tidal CO 2 and end tidal O 2 independently of each other and independently of minute ventilation.
- gas concentrations described herein may be referred to as partial pressures (e.g. PCO 2 ) or as fractional concentrations (e.g FCO 2 ).
- partial pressure e.g. PCO 2
- fractional concentrations e.g FCO 2
- None of these patents disclose means to set gas flows and gas concentrations into a circuit to attain a target end tidal fractional concentration of CO 2 (FTETCO 2 ) and/or target end tidal fractional concentration of O 2 (FTETO 2 ) for a given minute ventilation ( VE ). This is required for a number of applications as will be enumerated below. For illustrations purposes, will take the example of one such application: measuring cerebrovascular reactivity.
- Cerebral blood flow is closely regulated by metabolic demands of the brain tissue. CBF also responds to changes in arterial PCO 2 and PO 2 . The extent of the change in CBF in response to a stimulus is termed cerebrovascular reactivity (CVR). CVR may be a sensitive indicator of abnormal vessels such as vascular dysplasia or tissue abnormalities such as brain swelling and cancer. Quantitatively mapping CVR throughout the brain using imaging techniques such as magnetic resonance imaging (MRI) could identify areas of abnormal CVR. Brain blood vessel diameter responds to changes in blood PO 2 as well as blood PCO 2 . Blood PO 2 and blood PCO 2 are strongly tied to end tidal concentrations of O 2 and CO 2 respectively. Present methods of inducing high PETCO 2 control PETO 2 poorly and do not control PCO 2 and PO 2 independently.
- CVR cerebrovascular reactivity
- a second traditional method of changing PCO 2 is inspiring gas mixtures containing CO 2 via a facemask. This is known to result in a highly variable ventilatory response between subjects leading to a large variability in PETCO 2 . Furthermore, inhaling CO 2 changes the minute ventilation (VE) resulting also in variability in blood PO 2 . Oxygen is a potent vasoconstrictor and confounds the interpretation of the relationship between PCO 2 and brain blood flow. Therefore, neither breath-holding nor inhaling a gas mixture containing CO 2 provide suitable conditions for a consistent, repeatable quantitative test for CVR.
- Gas forcing depends on a feedback loop.
- Feedback loops can have inherent instability depending on the gain and time constant of the system, and are prone to drift and oscillation of end-tidal values.
- Sequential gas delivery method 1) A more recent method introduced by Vesely et al.(l) solved some of these problems. They used O 2 flow to a sequential gas delivery (SGD) circuit to produce rapid changes in PETCO 2 between two known levels (30-50 mmHg). (A SGD circuit provides (at least) two gases through two limbs. The gas from the first limb (G 1 ) is provided first, and if the subjects breathing exceeds the available first gas, the balance of that breath is made up of the second gas (G 2 ). The second gas may be previously exhaled gas collected in a reservoir on the second limb.) To reduce PCO 2 , they asked their patients to hyperventilate while providing large O 2 flows into the SGD.
- SGD sequential gas delivery
- the method of Vesely et al uses 2 gases and the manipulation of flow into the circuit to change end tidal CO 2 values. With this method, if the total flow is set, then i) varying the inspired PCO 2 changes the inspired PO 2 . ii) PETO 2 cannot be determined independently of PETCO 2 . iii) PETO 2 and PETCO 2 cannot be varied independently.
- the invention is directed to a method of inducing a target end tidal concentration, or maintaining the end tidal concentration at a target level, of a gas X in a patient comprising the steps of: a) setting the source gas flow into a partial re-breathing circuit at a rate equal to or less than the patient's minute ventilation; b) setting the concentration of said gas X in the source gas to a predetermined level corresponding to the target end tidal concentration of gas X; c) delivering the source gas to the patient through said circuit.
- the invention is directed to a method of inducing target end tidal concentrations, or maintaining end tidal concentrations at a target level, of a plurality of gases in a patient comprising: a) setting the source gas flow into a partial re-breathing circuit at a rate equal to or less than the patient's minute ventilation; b) setting the concentration in the source gas, of each gas whose target is being induced or maintained, to a predetermined level to attain the target end tidal concentration of that gas; c) delivering the source gas to the patient through said circuit.
- the concentration in the source gas, of each gas whose end tidal concentration in the patient is being set to or maintained at a target may be set by using one or more pre-mixed gases as the source gas, the said pre-mixed gas having concentrations so as to provide the required target end tidal concentrations.
- the concentrations in the source of each gas whose end tidal concentration in the patient is being set to or maintained at a target may be set by blending the source gas from a set of component gases.
- the invention may be employed to simultaneously maintain or change the end tidal concentrations of two gases independently of one another.
- the invention may be employed to maintain the end tidal concentration of a first gas X, while the end tidal concentration of at least one second gas Y is changed from a first target to a second target, by altering the composition of the source gas so that the concentration of the at least one second gas Y is changed.
- the concentration of one of more gases in the source gas may be controlled to achieve a particular target end tidal concentration of those gases when such concentration of such gases in the source are predetermined and set based one or more steps described herein.
- concentration of said gas X is set using one formula: VX
- FG 1 X F x ETX -- ⁇ - ⁇ VG 1
- FG 1 X is the concentration of gas X in the source gas G 1
- VX is the patient's minute production of the physiologically produced gas X
- FTETX is the target end tidal concentration of said gas X
- VG 1 is the flow rate of the source gas.
- An example of one such gas would be CO 2 .
- the concentration in the source gas of gases that are physiologically consumed by the patient are set using the formula:
- FG 1 X F 1 ETX + - ⁇ VG 1
- FG 1 X is the concentration of gas X in the source gas G 1
- VX is the patient's minute consumption of gas X
- FTETX is the target end tidal concentration of gas X
- VG 1 is the flow rate of the source gas.
- the patient's minute production of a physiologically produced gas or minute consumption of a physiologically consumed gas may be estimated based on height and weight, or other parameters, or measured directly.
- the source gas is, at any given time, made up of pre-mixed gases delivered individually or a blend of component gases, is a function of the capability of the apparatus (the apparatus may be adapted to accommodate one or both capabilities depending on its intended use) but is otherwise immaterial to the practice of the invention.
- the source gas flow into me breathing circuit preferably has a minimum safe concentration of O 2 , for example 10%.
- the source gas is made up of blended component gases (examples of sets of components gases for providing a full array of target end tidals are described below), at least the most frequently used and preferably each of the component gases comprises a minimum safe concentration of O 2 .
- the invention is directed to a method of changing an end tidal concentration of a gas X in a patient comprising setting the source gas flow into a partial rebreathing circuit at a rate equal to or less than the patient's minute ventilation and providing a first concentration of said gas X in the source gas and delivering the source gas to the patient through said circuit in order to effect a first end tidal concentration of said gas X.
- the further step of providing at least one second different concentration of said gas X in the source gas and delivering the source gas to the patient through said circuit in order to effect a second end tidal concentration of said gas X conveniently enables a diagnostic assessment to be made by measuring a physiological parameter at two end tidal levels of said gas X.
- the invention is directed to diagnostic methods employing any of the aforementioned methods of the invention and the various embodiments of those methods described herein and to apparatus adapted to carry out the method and components thereof, optionally including component gases, assembled to carry out the method.
- a method to measure cerebrovascular reactivity comprising controlling the end tidal CO 2 and O 2 levels of a subject using one of the aforementioned methods and monitoring a blood oxygen level dependent (BOLD) MRI signal intensity,
- a method to measure occulovascular reactivity comprising controlling the end tidal CO 2 and O 2 levels of a subject using one of the aforementioned methods and monitoring occulovascular blood flow.
- a method to measure a beneficial level of oxygenation to tissues for the purpose of radiotherapy or chemotherapy comprising controlling the end tidal CO 2 and O 2 levels of a subject using one of the aforementioned methods and monitoring oxygenation or blood flow in the tumor.
- end tidal CO 2 and O 2 levels are controlled independently of each other.
- the end tidal CO 2 levels may be changed while the end tidal O 2 levels are kept constant or the end tidal O 2 levels may be changed while the end tidal CO 2 levels are kept constant or the end tidal O 2 levels and the end tidal CO 2 levels may be changed simultaneously.
- the invention is directed to a therapeutic method comprising any of the aforementioned methods for controlling end tidal gas concentrations, for example a therapeutic method comprising using such a method to set the end tidal O 2 and CO 2 levels to pre-determined levels that provide a beneficial oxygenation level or blood flow level to tissues for the purpose of radiotherapy or chemotherapy.
- the partial re- breathing circuit is a sequential gas delivery circuit and the apparatus includes means for controlling the rate of flow of the source gas into the circuit and means for controlling the concentration of said gases in the source gas flow.
- the apparatus further comprises means for monitoring pressure in the breathing circuit and optionally further comprises means for measuring the patient's end tidal gas concentrations.
- the method above may further comprise measuring the end tidal gas concentrations and using feedback control to increase or decrease the concentrations of a particular gas so as to minimize the difference between the current end tidal concentration and the target end tidal concentration, for example so as to effect a more rapid change in target end tidal levels.
- Figure IA shows a rebreatbing sequential gas delivery circuit.
- Figure IB shows a non-rebreathing sequential gas delivery circuit.
- FIG. 2 shows the preferred embodiment of the apparatus.
- FIG. 3 shows an alternate embodiment of the apparatus.
- Figure 4 shows data from a subject using the apparatus and method, with constant P E ⁇ 2 and changes in levels of PETCO 2 .
- Figure 5 shows data from a subject using the apparatus and method, with constant
- PETCO 2 and changes in levels of P ET 0 2 .
- Figure 6 shows data from a subject using the apparatus and method, with simultaneous controlled changes in PETCO 2 and PETO 2 .
- the subject or patient preferably breathes through a breathing valve manifold with breathing tubes (herein referred to as a breathing circuit) known as a partial rebreathing circuit.
- a breathing circuit a breathing valve manifold with breathing tubes
- a partial rebreathing circuit a breathing circuit
- the subject breathes on a particular type of partial rebreathing circuit known as a sequential gas delivery (SGD) circuit, whose functions will be reviewed briefly.
- SGD sequential gas delivery
- Figure IB illustrates the principles of a non-rebreathing sequential gas delivery circuit.
- the expiratory one-way valve (30) opens and gas is exhaled to atmosphere; meanwhile, the source gas enters the source gas port (32) and is stored in the source gas reservoir (33).
- Figure IA illustrates the homologous circuit where exhaled gas is used as reserve gas. With this circuit, during exhalation, exhaled gas is directed into an exhaled gas reservoir (28) and made available to act as reserve gas.
- the one-way inspiratory valve (31) opens and source gas from the source gas port (32) and the source gas reservoir (33) are inhaled.
- the difference between VE and source gas flow is made up of reserve gas which is presented through crossover valve (29) in the rebreathing circuit or via demand valve (35) in the non rebreathing circuit.
- Source gas and reserve gas are inhaled sequentially: at the beginning of inhalation, gas is inhaled from the fresh gas flow inlet and the fresh.gas reservoir.
- Reserve gas in the non rebreathing circuit is comprised of gas that has similar properties to exhaled gas.
- the present invention describes a method for independent control of end tidal (end of exhalation) gas concentrations of a subject.
- the discussion herein describes the method particularly as it pertains to control of CO 2 and O 2 , although those skilled in the art will recognize that the method can be equally applied to control of other gases in the subject.
- the method comprises:
- VG 1 flow rate of the source gas (VG 1 ) into a partial rebreathing circuit, preferably a sequential gas delivery circuit, on which the subject is breathing, equal to or less than the subject's average VE .
- This may be . accomplished by adjusting the source gas flow until the source gas reservoir of a sequential gas delivery circuit just empties on each breath, or alternatively, a flowmeter may be interposed between the subject and the circuit.
- a partial rebreathing circuit is required with the method since the end tidal concentrations when breathing on such a circuit become fixed (approximately fixed for most partial rebreathing ' circuits, and reliably fixed with sequential gas delivery circuits) and independent of minute ventilation (VE ) 5 provided the gas flow into the circuit is less than or equal to the VE .
- the end tidal concentrations become a function only of the gas concentrations of the source gas.
- the method makes use of the relationship known in the art that relates a rate of alveolar ventilation VA to the patient's fractional end tidal CO 2 concentration:
- G 1 Another way to view this is to split G 1 into a component with a flow rate equal to the resting VA and a component with the balance of the flow which is (G 1 - VA).
- the component that is equal to VA fresh" gas flow because it contributes to gas exchange, (RJ 1 / ) by virtue of having no CO 2 .
- This gas flow therefore determines the end tidal concentration according to Equation (4).
- the second component of G 1 consisting of the difference between the desired G 1 and the VA (G 1 - VA) requires a concentration of CO 2 that does not provide a gradient for gas exchange. Thus composed, it is considered a "neutral" gas flow ( VG ⁇ ).
- FG ! n CO 2 equal to that of alveolar gas (as approximated by end tidal gas) by definition would be "neutral" with respect to gas exchange.
- the concentration in the neutral gas must be equal to the target CO 2 concentration to maintain PETCO 2 at the target value
- Equation (4) the relationship between his target end tidal and alveolar ventilation is known from Equation (4).
- Equation (9) The method for determining FG 1 O 2 is analogous to determining FG 1 CO 2 with the exception that the sign on the FO 2 is reversed in Equation (9) reflecting the fact that O 2 is consumed by the body while CO 2 is produced by the body.
- Equation (9) the analogous form for Equation (9) as is pertains to O 2 is as follows:
- Equations 9 and 11 may be generalized to any gas that is physiologically produced (as is CO 2 ) or consumed (as is O 2 ) by the body.
- the general form of Equation 9 for inducing or maintaining a target end tidal concentration of a gas X that is physiologically produced by the body would thus be to set the concentration of gas X in the source gas (defined as FG 1 X ) using
- VX is the patient's minute production of gas X 5
- FJETX is the target end tidal concentration of gas X
- VG 1 is the flow rate of the source gas.
- Equation 11 for inducing or maintaining a target end tidal concentration of a gas X that is physiologically consumed by the body would thus be to set the concentration of gas X in the source gas (defined as FG 1 X ) using
- VX is the patient's minute production of gas X
- FjETX is the target end tidal concentration of gas X 5
- VG 1 is the flow rate of the source gas.
- the method above may be used to target particular end tidal concentrations, however, the targeting may be fine tuned, or the target may be reached more quickly, by measuring the end tidal gas concentrations and using feedback control to increase or decrease the concentrations of a particular gas so as to minimize the difference between the current end tidal concentration and the target end tidal concentration.
- Another aspect of the present invention is the selection of gases used to carry out the method. It will be appreciated by those skilled in the art that, for a given desired total flow, any combination of concentrations OfCO 2 and O 2 in the source gas may be achieved by mixing source gases consisting of pure O 2 , CO 2 and N 2 . However, pure CO 2 and pure N 2 contain no O 2 and thus if the gas blending apparatus were to fail and the patient were to inhale just a few breaths of either of these two gases, it would lead to severe hypoxemia and possibly death.
- One aspect of the present invention is the use of source gases each of which has at least a minimum concentration of O 2 determined to be the safe minimum level. Preferably, this level is at least 10%, but under certain controlled and monitored conditions, levels less than 10% might still be used.
- the gas concentrations are chosen subject to the following constraints: i. To achieve the maximum signal / noise ratio for diagnostics, the widest range of FETO2 and FETCO 2 values is desirable. ii. Each gas must have a minimum safe concentration of oxygen, such that if it is the only gas given, the subject will not be severely harmed. This is preferably about 10%. One gas (call it gas “C”) should have no more O 2 than this and a low level of CO 2 to achieve the combination of low target FTET 1 O 2 and low FTETCO 2 . iii. The minimum oxygen concentration of one gas (call it gas "A”) must be set so as to achieve the maximum FETO 2 desirable to give the patient, iv.
- Gas B One gas (call it Gas "B”) must also contain at least a high enough CO 2 concentration so as to be able to achieve the maximum F ET C ⁇ 2 desired.
- the concentration of CO 2 in Gas B is further constrained by the fact that, to get a high FETO 2 and high FETCO 2 simultaneously, a substantial amount of Gas A (high O 2 concentration) must be given, leaving less room for Gas B in the FG 1 .
- Gas A would need over a 90% concentration of O 2 and Gas B would need at least a 60% concentration of CO 2 .
- Gas. "A” must have a low CO 2 concentration since it contains a high O 2 concentration, and it may be desirable to have a high FETO 2 and low FETCO 2 , which cannot be achieved any other way once the constraints on gases B and C above are considered. v ⁇ . Therefore, based on the above constraints, the preferred method includes using gases with relative concentrations as described in Table 1 :
- Table 2 Definition of terms used to designate the O 2 and CO 2 concentrations in Gas A, Gas B and Gas C.
- Equations 11 and 9 The method summarized by Equations 11 and 9 are used to determine fractional concentrations of CO 2 and O 2 that have to be supplied in G 1 to attain target FTETCO 2 and F ⁇ ET ⁇ 2 , assuming the patient's or subject's VCO2 and VO2 are known.
- the total flow of source gas G 1 into the apparatus is the sum of the flows of the individual gases A, B and C.
- the flow of O 2 in the source gas is equal to the sum of the flows of O 2 from the individual gases. Therefore:
- Equations 1, 2 and 3 can be used to calculate flows required from each mixture to obtain a total flow ( VG ⁇ ) with O 2 concentration OfFG 1 O 2 and CO 2 concentration FG 1 CO 2 .
- gas combinations for component gases may be used, and the derivation above may be extended to the general case of any concentration for any gas in the component gas.
- the same method and approach that is described for O 2 can be applied to any other gas that is absorbed, including, but not limited to acetylene, carbon monoxide, nitrous oxide, anesthetic gases.
- target PCO 2 and target PO 2 target PN2 is also defined.
- the target partial pressure of any inert gas can be defined, for example, but not limited to argon, helium, and xenon.
- Another aspect of this invention is the use of the independent control of end tidal CO 2 and O 2 , N 2 or other gas levels to carry out diagnostic and therapeutic tests or carry out research in physiology.
- the CO 2 levels may be rapidly transitioned from low to high targets and back repeatedly while the subject's brain blood flow is measured using the Blood Oxygen Level Dependent (BOLD) MRI imaging technique. This produces a map of cerebrovascular reactivity.
- BOLD and transcranial Doppler for example can be used to measure the physiology of brain and other tissue blood flow response to changes in blood concentrations of CO 2 , O 2 , with or without the presence of other gases or substances in the blood.
- occulovascular reactivity may be measured by measuring blood flow in the retinal vessels with Doppler ultrasound, MRI or other devices known to those skilled in the art, at target concentrations of CO 2 , O 2 and other gases, with and without the presence of other substances in the blood.
- Another test involves manipulating O 2 levels in tumors and measuring beneficial oxygenation levels in the tumor using BOLD MRI signal or other methods known to those skilled in the art. This would identify blood gasses providing beneficial levels of blood flow and oxygenation to tumors, sensitizing them to destruction by radiotherapy or chemotherapy. This may additionally be combined with using the method during radiotherapy so as to reproduce the determined level of oxygenation.
- a standardized test allows the study of the normal physiology of control of blood flow to a tissue or organ that responds to CO 2 or O 2 .
- trans cranial Doppler, BOLD MRI, spin labeling, with MRI, Positron Emission Tomography or many other • • measurements known to those skilled in the art can be used to measure blood flow, oxygenation or metabolism of tissues and organs in response to known, reproducible changes in PO 2 and PCO 2 or other gases with this method.
- this invention provides the ability to provide standard, reproducible stimuli via the lung to vascular beds and other tissues.
- a standard set of stimuli allows the comparison of results in a subject over time, between patients or subjects in a group, of a group over time, and between groups being studied by different researchers. None of these advantages can be obtained from known methods that do not reliably provide reproducible stimuli.
- Equations 9 and 11 above disclose the method for determining the fractional concentrations of CO 2 and O 2 in the source gas based on the target end tidal concentrations and the patient's rate OfO 2 consumption and CO 2 production. It may be desirable for performance of certain diagnostic tests to assume that a particular patient population has a small range of values for CO 2 production and O 2 consumption, or to ignore the small variations that the differences in these values might make to the resulting end tidal concentrations. It would then be possible to use a plurality of gas mixtures with predetermined concentrations of gas to achieve particular sets of targets.
- the apparatus consists of source gases chosen to provide the maximum range of combinations of targets for the end tidal gases, a gas blending device and a partial rebreathing circuit.
- the gases to be controlled are O 2 and CO 2 .
- three pressurized gases A, B and C are connected to the gas blending apparatus (1).
- gases A, B and C are delivered to the blender (1) at flows QA , QB and Qc that are regulated by flow controllers (6A), (6B) and (6C) via control inputs (3A), (3B) and (3C) respectively.
- These flow controllers may be of many types known in the art, but are preferably mass flow controllers to enhance precision.
- Flows of QA , QB and Qc are determined according to the present method for target FETCO 2 and FETO ⁇ at each phase in the sequence.
- the blend of QA , QB and Qc results in FG 1 .
- the resulting mixture, G 1 leaves the blender (l).yia an output hose (7) and is delivered to the gas inlet (8) of the partial rebreathing circuit (9).
- the partial rebreathing circuit is a sequential gas delivery circuit.
- inspiratory one-way valve (10) opens and the first part of the breath comes from the gas inlet (8) and G 1 reservoir (11). IfVE >exceeds VG 1 , the G 1 reservoir
- expiratory one-way valve (14) opens and expired gases are either collected in the exhaled gas reservoir (12), or in the case of a non-rebreathing SGD, they are vented. Meanwhile, G 1 collects in the G 1 source gas reservoir (11).
- Optional pressure sampling line (15) and pressure transducer (17) can be inserted at the patient-circuit . interface to aid in synchronization of changes in gas flows with the breath.
- gas may be sampled via line (16) connected to an optional CO 2 /O 2 analyzer (18). Peak detection algorithm can use signals from pressure transducer (17) or gas analyzer to detect breaths and pick end-tidal values for O2 and CO 2 . Data can be analyzed on- or offline and displayed on a computer screen (4).
- three-way solenoid valve (2) is electronically controlled by connection (3S) from machine intelligence (4) and is either open to air source (5) or to the manifold (82) collecting gas from gas sources A, B and C.
- connection (3S) from machine intelligence (4) and is either open to air source (5) or to the manifold (82) collecting gas from gas sources A, B and C.
- the apparatus When the apparatus is in the standby mode, the patient receives air flow which is regulated by flow controller (6) via control input (84).
- premixed gases with concentrations to achieve the desired targets can be used with an alternative apparatus described in Figure 3.
- individual concentrations of O 2 and CO2 in the G 1 gas measured among different patients will depend on patient's VO 2 and VCO 2 .
- apparatus described in Figure 3 allows precise control of FG 1 according to the patient's VO 2 and FCO 2 or estimate thereof.
- a set of premixed gases (5 are shown, but one is needed for each set of target end tidal concentrations)
- D, E, F, G and H containing premixed mixtures of O 2 , CO 2 and N 2 equal to those required in the G 1 gas during each phase of the sequence, are connected to gas blender (1).
- Two-way solenoid valves (25D 5 25E 5 25F, 25G 5 25H) control the flow of gases D, E, F 5 G and H.
- the two-way solenoid valves (25) are controlled by machine intelligence (4), which contains pre-programmed information about the order and duration of opening of each individual valve.
- Gas flow to the circuit (9) is regulated by a flow controller (26).
- Optional three-way solenoid valve (23) is electronically controlled via machine intelligence (4) and may be open to optional air . source (5) during an optional stand by phase or to the gases coming through solenoids (25). The rest of the apparatus is the same as in Figure 2 .
- Figures 4-6 show experimental data obtained from a subject whose end tidal values were controlled and set to target levels.
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
A method and apparatus is disclosed that induces target 'end tidal' (end of exhalation) gas concentrations, and in particular, end tidal oxygen concentrations and end tidal carbon dioxide concentrations, in a subject independent of one another. Additionally, the establishment of the target may be independent of minute ventilation. The method can, be used to induce rapid sequential changes in both target O2 and CO2. Subjects need not change their minute ventilation to attain changes in target O2 and CO2. In addition, when increases in minute ventilation do occur, the end tidal O2 and CO2 remain at target levels. The methods comprise setting the flow of source gas into a partial rebreathing circuit on which the patient is breathing at a rate equal or greater than the minute ventilation of the patient, and determining prospectively the concentrations of CO2 and O2 in the source gas to achieve the end tidal targets. An apparatus is provided to control the flow of source gases. The source gases are chosen so as to have a safe minimum concentration of O2 .
Description
TITLE OF INVENTION
A NEW METHOD AND APPARATUS TO ATTAIN AND MAINTAIN TARGET END TIDAL GAS CONCENTRATIONS
FIELD OF INVENTION
The invention disclosed herein relates to the field of blood gas control, which further relates to a number of fields of medical diagnostics and treatment. Changes in end tidal CO2 and/or O2 can be used to monitor vascular reactivity in retinal vessels and other vascular beds as detected by various retinal blood flow and other vascular flow sensors. Similarly, changes in end tidal CO2 and/or O2 can be used to monitor changes on organ or tissue function by measuring such factors as heart rate variability, skin conductivitys
hormone levels, organ temperature, plethysmography and other measurements known to physiologists and others skilled in the art.
BACKGROUND OF THE INVENTION
The present invention relates to a method to control the end tidal CO2 and end tidal O2 independently of each other and independently of minute ventilation.
It should be noted that gas concentrations described herein may be referred to as partial pressures (e.g. PCO2) or as fractional concentrations (e.g FCO2 ). Those skilled in the art will recognize the relationship between the two in that partial pressure = fractional concentration x ambient pressure.
Ordinarily, when minute ventilation increases, the partial pressure of end tidal CO2 (PETCO2) decreases and partial pressure of end tidal O2 (PETO2) increases. Fisher [for example, US Patent 6622725)], describes fixing fresh gas flowing into a partial rebreathing circuits such as the sequential gas delivery circuit in order to maintain constant PETCO2 in the face of increases in minute ventilation on the part of the subject. Fisher [Canadian Application 2,346,517] also describes means of keeping PETO2 constant at a given attained level despite increases in minute ventilation. None of these patents disclose means to set gas flows and gas concentrations into a circuit to attain a target end tidal fractional concentration of CO2 (FTETCO2) and/or target end tidal fractional concentration of O2 (FTETO2) for a given minute ventilation ( VE ). This is required for a number of applications as will be enumerated below. For illustrations purposes, will take the example of one such application: measuring cerebrovascular reactivity.
Cerebral blood flow (CBF) is closely regulated by metabolic demands of the brain tissue. CBF also responds to changes in arterial PCO2 and PO2. The extent of the change in CBF in response to a stimulus is termed cerebrovascular reactivity (CVR). CVR may be a sensitive indicator of abnormal vessels such as vascular dysplasia or tissue abnormalities such as brain swelling and cancer. Quantitatively mapping CVR throughout the brain using imaging techniques such as magnetic resonance imaging (MRI) could identify areas of abnormal CVR.
Brain blood vessel diameter responds to changes in blood PO2 as well as blood PCO2. Blood PO2 and blood PCO2 are strongly tied to end tidal concentrations of O2 and CO2 respectively. Present methods of inducing high PETCO2 control PETO2 poorly and do not control PCO2 and PO2 independently.
Brief review of current methods of changing blood PCO2 and PO2 via control of the lungs:
A: Breath-holding methods:
The simplest method for inducing changes in PCO2 during Magnetic Resonance Imaging (MRI) is breath-holding. As there is a rapid drift in the baseline MRI signal, changes in MRI signal resulting from changes in brain blood flow can be detected only by rapidly alternating the stimulus between "control" and "test" values. With respect to PCO2, this requires rapid step changes in PCO2, preferably maintaining PO2 constant. Cycle times of 3 min have been reported by Vesely et al (1) to be suitable, but shorter cycle times would be preferred. Breath-holding induces an increase in PCO2 but it is not well suited to measuring CVR. The rise in blood PCO2 during breath-holding is very slow as it is dependent on body CO2 production ( FCO2 ), which is small compared to body capacitance for CO2. During breath holding, alveolar PO2 declines progressively. As CO2 production, CO2 capacitance and the tolerable breath-holding time varies from patient to patient, so will the final blood PCO2 and PETO2. As there is no gas sampling during breath-holding the blood PCO2 and PO2 is unknown for the duration of the breath- hold so it is not possible to relate the MRI signal strength to PCO2 or PO2, a requirement for the calculation of CVR.
B: Inhaling CO2
A second traditional method of changing PCO2 is inspiring gas mixtures containing CO2 via a facemask. This is known to result in a highly variable ventilatory response between subjects leading to a large variability in PETCO2. Furthermore, inhaling CO2 changes the minute ventilation (VE) resulting also in variability in blood PO2. Oxygen is a potent vasoconstrictor and confounds the interpretation of the relationship between PCO2 and brain blood flow.
Therefore, neither breath-holding nor inhaling a gas mixture containing CO2 provide suitable conditions for a consistent, repeatable quantitative test for CVR.
C: Gas forcing
Since the effects of inhaling a Cθ2-containing gas mixture on increasing PCO2 can be overcome by increasing minute ventilation, one can introduce a feedback loop to adjust the inhaled PCO2 to effect a target PETCO2. This is referred to as "gas forcing"(2) . Gas forcing has been shown to be effective in imposing target PETO2 and target PETCO2 independent of minute ventilation. However, it does have some drawbacks with respect to measuring CVR:
1) Gas forcing depends on a feedback loop. Feedback loops can have inherent instability depending on the gain and time constant of the system, and are prone to drift and oscillation of end-tidal values.
2) Gas forcing is usually applied in a chamber or requires a hood over the head. As such, there is a large volume of gas that needs to be replaced rapidly for each change in inspired PCO2. This necessitates very large flows of gases and very precise flow controllers for each gas (such as N2, O2 and CO2 if only these gases are controlled). This is very expensive and cumbersome, and an error which leads to presentation of pure N2 or pure CO2 could be deadly.
3) Gas forcing requires the construction of a special chamber that is not available commercially and has been custom built for research purposes. This is available only in a few places in the world.
4) The requirement for specific air-tight chambers, large gas flow controllers, massive volumes of gases, and complex computer control algorithms makes gas forcing too cumbersome to be suitable for use in a radiology, MRI and ophthalmology suites.
5) The time constant for changes in alveolar gas concentrations is too long to be suitable for use with MRI.
D: Sequential gas delivery method:
1) A more recent method introduced by Vesely et al.(l) solved some of these problems. They used O2 flow to a sequential gas delivery (SGD) circuit to produce rapid changes in PETCO2 between two known levels (30-50 mmHg). (A SGD circuit provides (at least) two gases through two limbs. The gas from the first limb (G1) is provided first, and if the subjects breathing exceeds the available first gas, the balance of that breath is made up of the second gas (G2). The second gas may be previously exhaled gas collected in a reservoir on the second limb.) To reduce PCO2, they asked their patients to hyperventilate while providing large O2 flows into the SGD. To raise the PCO2, they provided a bolus of CO2 by briefly changing the composition of the gas entering the circuit and then maintained the raised PCO2 by controlling the flow into the SGD. While this allowed transitions to a new PETCO2, the lowering and raising of O2 flows into the circuit to control PETCO2 and the required changes in VE caused alveolar, and thus end tidal, O2 concentrations to change during the protocol despite near constant inspired O2 concentration. For example, when O2 flow was restricted in order to keep the PETCO2 high, the PETO2 tended to drift down (as O2 consumption stays constant in the face of reduced O2 delivery). When patients hyperventilated to lower the PETCO2, the increased O2 flow into the circuit resulted in a rise of PETO2 (as O2 consumption stays constant and O2 delivery is increased). The changes in blood PO2 have an effect on the MRI signal independent of brain blood flow confounding the interpretation with respect to blood flow.
There are additional practical problems with this method:
1) Subjects must change their VE frequently during the protocol. It may be difficult for most people to comply adequately with this.
2) Not adequately following breathing instructions results in not meeting target PCO2 values
3) Not responding to breathing instructions quickly enough invalidate the MRI data.
4) The method of Vesely et al uses 2 gases and the manipulation of flow into the circuit to change end tidal CO2 values. With this method, if the total flow is set, then i) varying the inspired PCO2 changes the inspired PO2. ii) PETO2 cannot be determined independently of PETCO2. iii) PETO2 and PETCO2 cannot be varied independently.
Reference List
(1) Vesely A, Sasano H, Volgyesi G, Somogyi R9 Tesler J5 Fedorko L et al. MRI mapping of cerebrovascular reactivity using square wave changes in end-tidal PC02. Magn Reson Med 2001; 45(6):1011-1013.
(2) Robbins PA, Swanson GD5 Howson MG. A prediction-correction scheme for forcing alveolar gases along certain time courses. J Appl Physiol 1982; 52(5):1353- 1357.
SUMMARY OF THE INVENTION
In one aspect, the invention is directed to a method of inducing a target end tidal concentration, or maintaining the end tidal concentration at a target level, of a gas X in a patient comprising the steps of: a) setting the source gas flow into a partial re-breathing circuit at a rate equal to or less than the patient's minute ventilation; b) setting the concentration of said gas X in the source gas to a predetermined level corresponding to the target end tidal concentration of gas X; c) delivering the source gas to the patient through said circuit.
In a second aspect, the invention is directed to a method of inducing target end tidal concentrations, or maintaining end tidal concentrations at a target level, of a plurality of gases in a patient comprising: a) setting the source gas flow into a partial re-breathing circuit at a rate equal to or less than the patient's minute ventilation; b) setting the concentration in the source gas, of each gas whose target is being induced or maintained, to a predetermined level to attain the target end tidal concentration of that gas; c) delivering the source gas to the patient through said circuit.
As further described herein, according to one embodiment of the invention, the concentration in the source gas, of each gas whose end tidal concentration in the patient is being set to or maintained at a target, may be set by using one or more pre-mixed gases as the source gas, the said pre-mixed gas having concentrations so as to provide the required target end tidal concentrations. Alternatively, the concentrations in the source of each gas whose end tidal concentration in the patient is being set to or maintained at a target, may be set by blending the source gas from a set of component gases.
The invention may be employed to simultaneously maintain or change the end tidal concentrations of two gases independently of one another. Alternatively, the invention may be employed to maintain the end tidal concentration of a first gas X, while the end tidal concentration of at least one second gas Y is changed from a first target to a second target, by altering the composition of the source gas so that the concentration of the at least one second gas Y is changed.
As first described above, according to one aspect of the invention the concentration of one of more gases in the source gas may be controlled to achieve a particular target end tidal concentration of those gases when such concentration of such gases in the source are predetermined and set based one or more steps described herein. As described below, to achieve a target end tidal of a gas X that is physiologically produced by the patient's body, the concentration of said gas X is set using one formula:
VX
FG1X = FxETX --^- τ VG1 where FG1X is the concentration of gas X in the source gas G1, VX is the patient's minute production of the physiologically produced gas X, FTETX is the target end tidal concentration of said gas X, and VG1 is the flow rate of the source gas. An example of one such gas would be CO2 .
The concentration in the source gas of gases that are physiologically consumed by the patient are set using the formula:
FG1X = F1ETX + - τ VG1 where FG1X is the concentration of gas X in the source gas G1 , VX is the patient's minute consumption of gas X9 FTETX is the target end tidal concentration of gas X and VG1 is the flow rate of the source gas.
The patient's minute production of a physiologically produced gas or minute consumption of a physiologically consumed gas may be estimated based on height and weight, or other parameters, or measured directly.
Whether the source gas is, at any given time, made up of pre-mixed gases delivered individually or a blend of component gases, is a function of the capability of the apparatus (the apparatus may be adapted to accommodate one or both capabilities depending on its intended use) but is otherwise immaterial to the practice of the invention. In either case according to one preferred embodiment of the invention, the source gas flow into me breathing circuit preferably has a minimum safe concentration of O2 , for example 10%. Where the source gas is made up of blended component gases (examples of sets of components gases for providing a full array of target end tidals are described below), at least the most frequently used and preferably each of the component gases comprises a minimum safe concentration of O2.
In a broader aspect, to achieve one or more changes in the end tidal concentration of a given gas in the source without achieving a pre-determined change, the invention is directed to a method of changing an end tidal concentration of a gas X in a patient comprising setting the source gas flow into a partial rebreathing circuit at a rate equal to or less than the patient's minute ventilation and providing a first concentration of said gas X in the source gas and delivering the source gas to the patient through said circuit in order to effect a first end tidal concentration of said gas X.
In a preferred embodiment of the latter method, the further step of providing at least one second different concentration of said gas X in the source gas and delivering the source gas to the patient through said circuit in order to effect a second end tidal concentration of said gas X conveniently enables a diagnostic assessment to be made by measuring a physiological parameter at two end tidal levels of said gas X.
In other aspects, the invention is directed to diagnostic methods employing any of the aforementioned methods of the invention and the various embodiments of those methods described herein and to apparatus adapted to carry out the method and components thereof, optionally including component gases, assembled to carry out the method.
Preferred embodiments of such diagnostic methods include:
A method to measure cerebrovascular reactivity comprising controlling the end tidal CO2 and O2 levels of a subject using one of the aforementioned methods and monitoring a blood oxygen level dependent (BOLD) MRI signal intensity,
A method to measure occulovascular reactivity comprising controlling the end tidal CO2 and O2 levels of a subject using one of the aforementioned methods and monitoring occulovascular blood flow.
A method to measure a beneficial level of oxygenation to tissues for the purpose of radiotherapy or chemotherapy, comprising controlling the end tidal CO2 and O2 levels of
a subject using one of the aforementioned methods and monitoring oxygenation or blood flow in the tumor.
It will be appreciated that in the practice of the aforementioned diagnostic methods the end tidal CO2 and O2 levels are controlled independently of each other. For example, the end tidal CO2 levels may be changed while the end tidal O2 levels are kept constant or the end tidal O2 levels may be changed while the end tidal CO2 levels are kept constant or the end tidal O2 levels and the end tidal CO2 levels may be changed simultaneously.
In yet another aspect, the invention is directed to a therapeutic method comprising any of the aforementioned methods for controlling end tidal gas concentrations, for example a therapeutic method comprising using such a method to set the end tidal O2 and CO2 levels to pre-determined levels that provide a beneficial oxygenation level or blood flow level to tissues for the purpose of radiotherapy or chemotherapy.
In the practice of one embodiment of one of the aforementioned methods, the partial re- breathing circuit is a sequential gas delivery circuit and the apparatus includes means for controlling the rate of flow of the source gas into the circuit and means for controlling the concentration of said gases in the source gas flow. Optionally, the apparatus further comprises means for monitoring pressure in the breathing circuit and optionally further comprises means for measuring the patient's end tidal gas concentrations.
Optionally, the method above may further comprise measuring the end tidal gas concentrations and using feedback control to increase or decrease the concentrations of a particular gas so as to minimize the difference between the current end tidal concentration and the target end tidal concentration, for example so as to effect a more rapid change in target end tidal levels.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure IA shows a rebreatbing sequential gas delivery circuit.
Figure IB shows a non-rebreathing sequential gas delivery circuit.
Figure 2 shows the preferred embodiment of the apparatus.
Figure 3 shows an alternate embodiment of the apparatus.
Figure 4 shows data from a subject using the apparatus and method, with constant PEτθ2 and changes in levels of PETCO2. Figure 5 shows data from a subject using the apparatus and method, with constant
PETCO2 and changes in levels of PET02. Figure 6 shows data from a subject using the apparatus and method, with simultaneous controlled changes in PETCO2 and PETO2.
DETAILED DESCRIPTION OF THE INVENTION
In the present invention the subject or patient preferably breathes through a breathing valve manifold with breathing tubes (herein referred to as a breathing circuit) known as a partial rebreathing circuit. Preferably, the subject breathes on a particular type of partial rebreathing circuit known as a sequential gas delivery (SGD) circuit, whose functions will be reviewed briefly.
The non-rebreathing sequential gas delivery circuit was taught by Fisher [US 6354292]. The rebreathing sequential gas delivery circuits were taught by Fisher [US 6622725, US 6612308]. Figure IB illustrates the principles of a non-rebreathing sequential gas delivery circuit. During exhalation, the expiratory one-way valve (30) opens and gas is exhaled to atmosphere; meanwhile, the source gas enters the source gas port (32) and is stored in the source gas reservoir (33). Figure IA illustrates the homologous circuit where exhaled gas is used as reserve gas. With this circuit, during exhalation, exhaled gas is directed into an exhaled gas reservoir (28) and made available to act as reserve gas. During inhalation, the one-way inspiratory valve (31) opens and source gas from the source gas port (32) and the source gas reservoir (33) are inhaled. In both of these circuits, when VE exceeds source gas flow, the difference between VE and source gas flow is made up of reserve gas which is presented through crossover valve (29) in the rebreathing circuit or via demand valve (35) in the non rebreathing circuit. Source gas
and reserve gas are inhaled sequentially: at the beginning of inhalation, gas is inhaled from the fresh gas flow inlet and the fresh.gas reservoir. Reserve gas in the non rebreathing circuit is comprised of gas that has similar properties to exhaled gas.
Description of Method to Independently Control End-Tidal Gases
The present invention describes a method for independent control of end tidal (end of exhalation) gas concentrations of a subject. The discussion herein describes the method particularly as it pertains to control of CO2 and O2 , although those skilled in the art will recognize that the method can be equally applied to control of other gases in the subject.
The method comprises:
1. determining or estimating the subject's VCO2 and VO2
2. setting the flow rate of the source gas (VG1) into a partial rebreathing circuit, preferably a sequential gas delivery circuit, on which the subject is breathing, equal to or less than the subject's average VE . This may be . accomplished by adjusting the source gas flow until the source gas reservoir of a sequential gas delivery circuit just empties on each breath, or alternatively, a flowmeter may be interposed between the subject and the circuit.
3. setting the O2 and CO2 concentrations in the source gas (FG1O2 and FG1CO2 respectively) to concentrations determined using the methods described below
A partial rebreathing circuit is required with the method since the end tidal concentrations when breathing on such a circuit become fixed (approximately fixed for most partial rebreathing' circuits, and reliably fixed with sequential gas delivery circuits) and independent of minute ventilation (VE )5 provided the gas flow into the circuit is less than or equal to the VE . The end tidal concentrations become a function only of the gas concentrations of the source gas.
We will first describe the method for determining FG1CO2 . In order to carry out the method, one must first obtain values for the subject's CO2 production (FCO2) , which can be done by direct measurement (for example by analyzing a timed collection of exhaled gas for FCO2) or calculated from standard tables based on other anthropomorphic data such as weight and height.
The method makes use of the relationship known in the art that relates a rate of alveolar ventilation VA to the patient's fractional end tidal CO2 concentration:
This relationship states that for a given rate of alveolar ventilation, a particular end tidal concentration is produced. Lowering the alveolar ventilation raises FETCO2 and raising it lowers FETCO2.
In the present method, we determine what concentration of CO2 is required in the source gas to keep the FETCO2 level fixed at the target. Changing the CO2 level to a new target requires determining the new required CO2 concentration in the source gas. For example, consider a case where the patient has a resting VA witihi a corresponding resting end tidal
CO2. If we wish to increase the source gas flow ^ to greater than the subject's resting
VA , and we instruct the subject to breathe at a rate > ^ to assure that all of VGX reaches the alveoli, then G1 must have additional CO2 to prevent a reduction in PETCO2.
Another way to view this is to split G1 into a component with a flow rate equal to the resting VA and a component with the balance of the flow which is (G1 - VA). We call the component that is equal to VA "fresh" gas flow because it contributes to gas exchange, (RJ1/ ) by virtue of having no CO2. This gas flow therefore determines the end tidal concentration according to Equation (4). The second component of G1 consisting of the difference between the desired G1 and the VA (G1 - VA) requires a concentration of CO2
that does not provide a gradient for gas exchange. Thus composed, it is considered a "neutral" gas flow ( VG\ ). FG! nCO2 equal to that of alveolar gas (as approximated by end tidal gas) by definition would be "neutral" with respect to gas exchange.
Since there is no CO2 in FG1 / , VGl n is the source of all of the CO2 in G1 (Equation (6).
FG1 x FG1CO2 = VG\ x FG1HCO2 Equation (6)
The concentration in the neutral gas must be equal to the target CO2 concentration to maintain PETCO2 at the target value
FG1 x FG1CO2 = VG\ x FTETCO2 Equation (7)
and the rate of flow of neutral gas is the difference between the rate of flow of the source gas and the rate of his alveolar ventilation, or
VG\ = [ VG1 - VA ] Equation (7b)
Allows us to rewrite Equation (7) as:
VG1 x FG1CO2= [ FG1 - VA ] x FTETCO2 Equation (7c)
Also, the relationship between his target end tidal and alveolar ventilation is known from Equation (4).
VA = Equation (4)
FTETCO2 4 V ;
Therefore, substituting Equation (4) in equation (7c) we get:
VG1X FG1CO2= [VG1 - VC°2 ] x FTETCO2 Equation (8)
FTETCO2
Dividing both sides by ^ gives:
FG1CO2 = F1ETCO2 - ^SQ- Equation (9)
This argument should hold generically for any gas that is absorbed by the body as well. In practice, it is preferable to have the patient breathing at a rate greater than their resting breathing rate in order to achieve end tidal CO2 targets below their resting levels. Additionally, having the patient breathe faster enables more rapid transitions between end tidal levels, particularly when moving from higher to lower CO2 targets, since the breathing rate becomes the limiting factor when giving the lowest concentration (i.e. 0%) of CO2 possible.
We now describe the method for determining FG1O2 . In order to carry out the method, one must first obtain values for the subject's O2 consumption (FO2 ) , which can be done by direct measurement (for example by collecting exhaled gas in a bag and analyzing its concentration), calculated from standard tables based on other physiological data such as weight and height, or determined from FCO2 and the Respiratory Quotient (RQ) which relates FO2 to VCΟ2 and is usually estimated as having a value of 0.8 in most people.
The method for determining FG1O2 is analogous to determining FG1CO2 with the exception that the sign on the FO2 is reversed in Equation (9) reflecting the fact that O2 is consumed by the body while CO2 is produced by the body. Thus the analogous form for Equation (9) as is pertains to O2 is as follows:
FG1O2 = FxETO2 +-^- Equation (11)
It will be appreciated by those skilled in the art that Equations 9 and 11 may be generalized to any gas that is physiologically produced (as is CO2 ) or consumed (as is O2 ) by the body. The general form of Equation 9 for inducing or maintaining a target end
tidal concentration of a gas X that is physiologically produced by the body would thus be to set the concentration of gas X in the source gas (defined as FG1X ) using
. FG1X Equation (12)
where VX is the patient's minute production of gas X5 FJETX is the target end tidal concentration of gas X, and VG1 is the flow rate of the source gas.
The general form of Equation 11 for inducing or maintaining a target end tidal concentration of a gas X that is physiologically consumed by the body would thus be to set the concentration of gas X in the source gas (defined as FG1X ) using
FG1X = FTETX + ~ Equation (13)
where VX is the patient's minute production of gas X, FjETX is the target end tidal concentration of gas X5 and VG1 is the flow rate of the source gas.
Optionally, it will be appreciated by those skilled in the art that the method above may be used to target particular end tidal concentrations, however, the targeting may be fine tuned, or the target may be reached more quickly, by measuring the end tidal gas concentrations and using feedback control to increase or decrease the concentrations of a particular gas so as to minimize the difference between the current end tidal concentration and the target end tidal concentration.
Selection of Source Gases
Another aspect of the present invention is the selection of gases used to carry out the method. It will be appreciated by those skilled in the art that, for a given desired total flow, any combination of concentrations OfCO2 and O2 in the source gas may be achieved by mixing source gases consisting of pure O2, CO2 and N2. However, pure CO2 and pure N2 contain no O2 and thus if the gas blending apparatus were to fail and the patient were to inhale just a few breaths of either of these two gases, it would lead to severe hypoxemia and possibly death. One aspect of the present invention is the use of source gases each of which has at least a minimum concentration of O2 determined to be
the safe minimum level. Preferably, this level is at least 10%, but under certain controlled and monitored conditions, levels less than 10% might still be used.
The gas concentrations are chosen subject to the following constraints: i. To achieve the maximum signal / noise ratio for diagnostics, the widest range of FETO2 and FETCO2 values is desirable. ii. Each gas must have a minimum safe concentration of oxygen, such that if it is the only gas given, the subject will not be severely harmed. This is preferably about 10%. One gas (call it gas "C") should have no more O2 than this and a low level of CO2 to achieve the combination of low target FTET1O2 and low FTETCO2. iii. The minimum oxygen concentration of one gas (call it gas "A") must be set so as to achieve the maximum FETO2 desirable to give the patient, iv. One gas (call it Gas "B") must also contain at least a high enough CO2 concentration so as to be able to achieve the maximum FETCθ2 desired. The concentration of CO2 in Gas B is further constrained by the fact that, to get a high FETO2 and high FETCO2 simultaneously, a substantial amount of Gas A (high O2 concentration) must be given, leaving less room for Gas B in the FG1. For example, to achieve a 7.5% FEτCO2 with a 90% FETO2 , Gas A would need over a 90% concentration of O2 and Gas B would need at least a 60% concentration of CO2 . v. The O2 concentration of Gas "B" must be low enough to enable producing in the subject the highest desirable FETCO2 and the lowest desirable FETO2. vi. Gas. "A" must have a low CO2 concentration since it contains a high O2 concentration, and it may be desirable to have a high FETO2 and low FETCO2 , which cannot be achieved any other way once the constraints on gases B and C above are considered. vϋ. Therefore, based on the above constraints, the preferred method includes using gases with relative concentrations as described in Table 1 :
Blending Source Gases to Achieve the Required Total Gas Concentrations of COg and O2
For the present discussion, we assume that the FO2 in Gas B and Gas C are set to achieve the lower bound of FTETO2, and FCO2 in Gas A and Gas C are both set to achieve the lower bound FTETCO2. Hence, the greatest range of FTETO2 and FTETCO2 occurs when FBO2 = FcO2 and FACO2 = FcCO2 . Table 2 is used to defines terns used to designate the O2 and CO2 concentrations in Gas A, Gas B and Gas C.
Table 2: Definition of terms used to designate the O2 and CO2 concentrations in Gas A, Gas B and Gas C.
The method summarized by Equations 11 and 9 are used to determine fractional concentrations of CO2 and O2 that have to be supplied in G1 to attain target FTETCO2 and FτETθ2, assuming the patient's or subject's VCO2 and VO2 are known.
The total flow of source gas G1 into the apparatus is the sum of the flows of the individual gases A, B and C.
The flow of O2 in the source gas is equal to the sum of the flows of O2 from the individual gases. Therefore:
VG1 x FG1O2 = QA X FAO2 + QB X FBO2 + Qc x FcO2 But since FcO2 = FBO2 this can be rewritten as
VG1 x FG1O2 = QA X FAO2 + (FG1- QA ) x FBO2 Which simplifies to
Λ YG1CFG1O2- FBO2) _ .. ,„
QA = — — Equation (1)
FAO2 -FBO2 H
The flow of CO2 in the source gas is equal to the sum of the flows in the individual gases. Therefore:
FG1X FG1CO2 = QA X FACO2+ QB X FBCO2 + QC X FCO2 But since FACO2 = FcCO2 this can be rewritten as
VG1 x FG1CO2 = QB X FBCO2 + (VG1- QB ) x FACO2
This simplifies to
Λ -. +. ,„
Finally,
Qc = VG1- QA - QB Equation (3)
Equations 1, 2 and 3 can be used to calculate flows required from each mixture to obtain a total flow ( VG^ ) with O2 concentration OfFG1O2 and CO2 concentration FG1CO2. It should be appreciated by those skilled in the art that other gas combinations for component gases may be used, and the derivation above may be extended to the general case of any concentration for any gas in the component gas. The same method and
approach that is described for O2 can be applied to any other gas that is absorbed, including, but not limited to acetylene, carbon monoxide, nitrous oxide, anesthetic gases. It is recognized that by defining target PCO2 and target PO2, target PN2 is also defined. In the same way, the target partial pressure of any inert gas can be defined, for example, but not limited to argon, helium, and xenon.
Another aspect of this invention is the use of the independent control of end tidal CO2 and O2 , N2 or other gas levels to carry out diagnostic and therapeutic tests or carry out research in physiology. What follows are examples that are not meant to be an exhaustive list of applications for instituting targeted blood gases. For example, the CO2 levels may be rapidly transitioned from low to high targets and back repeatedly while the subject's brain blood flow is measured using the Blood Oxygen Level Dependent (BOLD) MRI imaging technique. This produces a map of cerebrovascular reactivity. BOLD and transcranial Doppler, for example can be used to measure the physiology of brain and other tissue blood flow response to changes in blood concentrations of CO2, O2, with or without the presence of other gases or substances in the blood. Similarly, occulovascular reactivity may be measured by measuring blood flow in the retinal vessels with Doppler ultrasound, MRI or other devices known to those skilled in the art, at target concentrations of CO2, O2 and other gases, with and without the presence of other substances in the blood. Another test involves manipulating O2 levels in tumors and measuring beneficial oxygenation levels in the tumor using BOLD MRI signal or other methods known to those skilled in the art. This would identify blood gasses providing beneficial levels of blood flow and oxygenation to tumors, sensitizing them to destruction by radiotherapy or chemotherapy. This may additionally be combined with using the method during radiotherapy so as to reproduce the determined level of oxygenation. It is obvious that similar studies may be performed in any of the other responsive vascular beds in the body including but not limited to the skin, kidney, heart, lung and various abnormal congenital and acquired conditions such as tumours and vascular malformations.
Being able to achieve target end tidal PO2 and PCO2 allows the reproducibility of test conditions. This in turn allows the comparison of tests on one subject from one time to the next and between subjects. This reproducibility of the test enables the doctor, for the first time, to follow the progress of an abnormality, or a response to treatment. For example, in a patient with Moyamoya disease, an area of the brain develops abnormalities in blood vessels which can be identified by abnormal response to changes in PCO2. Repeated standardized tests to the same target PCO2 allows the doctor to identify changes in strength of response. In cranial artery stenosis, an area of the brain may lose its vascular reactivity as seen by response to BOLD imaging with MRI in response to changes in PCO2. The test can be repeated after surgery to identify the extent of recovery of vascular reactivity. If there are still areas of loss of reactivity, further surgery may be indicated.
A standardized test allows the study of the normal physiology of control of blood flow to a tissue or organ that responds to CO2 or O2. For example, trans cranial Doppler, BOLD MRI, spin labeling, with MRI, Positron Emission Tomography or many other • • measurements known to those skilled in the art can be used to measure blood flow, oxygenation or metabolism of tissues and organs in response to known, reproducible changes in PO2 and PCO2 or other gases with this method.
In summary, this invention provides the ability to provide standard, reproducible stimuli via the lung to vascular beds and other tissues. When combined with any of a long list of sensors, known to those skilled in the art, a standard set of stimuli allows the comparison of results in a subject over time, between patients or subjects in a group, of a group over time, and between groups being studied by different researchers. None of these advantages can be obtained from known methods that do not reliably provide reproducible stimuli.
Alternate Method Using Premixed Gases
Equations 9 and 11 above disclose the method for determining the fractional concentrations of CO2 and O2 in the source gas based on the target end tidal
concentrations and the patient's rate OfO2 consumption and CO2 production. It may be desirable for performance of certain diagnostic tests to assume that a particular patient population has a small range of values for CO2 production and O2 consumption, or to ignore the small variations that the differences in these values might make to the resulting end tidal concentrations. It would then be possible to use a plurality of gas mixtures with predetermined concentrations of gas to achieve particular sets of targets. For example, assuming all patients had a VO2 of 300 ml/min , VCO2 of 250 rtύVmin, and breathed at a rate of VE = 10 lpm, and given the following set of target end tidal concentrations of CO2 O2 , one might provide the following premixed gases each of which corresponded to one pair of targets. These gases may be provided to the patient in a predetermined sequence to perform a diagnostic test, for example.
Table: Sample Premixed Gases to Achieve Desired set of Targets
End Tidal Control Apparatus
Another aspect of the present invention is the apparatus used to carry out the method. The apparatus consists of source gases chosen to provide the maximum range of combinations of targets for the end tidal gases, a gas blending device and a partial rebreathing circuit. In the preferred embodiment, the gases to be controlled are O2 and CO2. With reference to Figure 2, three pressurized gases A, B and C are connected to the gas blending apparatus (1). When the method is conducted, gases A, B and C are delivered to the blender (1) at flows QA , QB and Qc that are regulated by flow controllers (6A), (6B) and (6C) via control inputs (3A), (3B) and (3C) respectively. These flow controllers may be of many types known in the art, but are preferably mass flow controllers to enhance precision.
Flows of QA , QB and Qc are determined according to the present method for target FETCO2 and FETOΪ at each phase in the sequence. The blend of QA , QB and Qc results in FG1. The resulting mixture, G1, leaves the blender (l).yia an output hose (7) and is delivered to the gas inlet (8) of the partial rebreathing circuit (9). In the preferred embodiment shown, the partial rebreathing circuit is a sequential gas delivery circuit. During inhalation, inspiratory one-way valve (10) opens and the first part of the breath comes from the gas inlet (8) and G1 reservoir (11). IfVE >exceeds VG1 , the G1 reservoir
(11) collapses during the breath and the balance of the breath comes from the exhaled gas G2 reservoir (12) via the crossover valve (13) or in the case of a non-rebreathing SGD from stored exogenous gas that approximates exhaled gas.
During exhalation, expiratory one-way valve (14) opens and expired gases are either collected in the exhaled gas reservoir (12), or in the case of a non-rebreathing SGD, they are vented. Meanwhile, G1 collects in the G1 source gas reservoir (11). Optional pressure sampling line (15) and pressure transducer (17) can be inserted at the patient-circuit . interface to aid in synchronization of changes in gas flows with the breath. Optionally, gas may be sampled via line (16) connected to an optional CO2/O2 analyzer (18). Peak detection algorithm can use signals from pressure transducer (17) or gas analyzer to detect breaths and pick end-tidal values for O2 and CO2. Data can be analyzed on- or offline and displayed on a computer screen (4).
Optionally, if it is desired to give the patient air during a stand by phase, three-way solenoid valve (2) is electronically controlled by connection (3S) from machine intelligence (4) and is either open to air source (5) or to the manifold (82) collecting gas from gas sources A, B and C. When the apparatus is in the standby mode, the patient receives air flow which is regulated by flow controller (6) via control input (84).
Alternate Embodiment
If it is desired to "hardwire" a particular sequence of target end tidal concentrations, premixed gases with concentrations to achieve the desired targets can be used with an
alternative apparatus described in Figure 3. For any given pattern of transitions and steady states, individual concentrations of O2 and CO2 in the G1 gas measured among different patients will depend on patient's VO2 and VCO2 . In order to accommodate for these differences, apparatus described in Figure 3 allows precise control of FG1 according to the patient's VO2 and FCO2 or estimate thereof.
With reference to Figure 3 a set of premixed gases (5 are shown, but one is needed for each set of target end tidal concentrations) D, E, F, G and H containing premixed mixtures of O2, CO2 and N2 equal to those required in the G1 gas during each phase of the sequence, are connected to gas blender (1). Two-way solenoid valves (25D5 25E5 25F, 25G525H) control the flow of gases D, E, F5 G and H. The two-way solenoid valves (25) are controlled by machine intelligence (4), which contains pre-programmed information about the order and duration of opening of each individual valve. Gas flow to the circuit (9) is regulated by a flow controller (26). Optional three-way solenoid valve (23) is electronically controlled via machine intelligence (4) and may be open to optional air. source (5) during an optional stand by phase or to the gases coming through solenoids (25). The rest of the apparatus is the same as in Figure 2 .
Figures 4-6 show experimental data obtained from a subject whose end tidal values were controlled and set to target levels.
Claims
1. A method of inducing a target end tidal concentration of a gas X in a patient comprising: a) setting the source gas flow into a partial rebreathing circuit at a rate equal to or less than the patient's minute ventilation b) setting the concentration of said gas X in the source gas to a predetermined level corresponding to the target end tidal concentration of gas X c) delivering the source gas to the patient through said circuit
2. The method of claim 1 wherein said gas X is a gas produced by the patient, and the
VX concentration of said gas X (FG1X) is set according to FG1X = FxETX — : — j- , where
VX is the patient's minute production of gas X5 FTETX is the target end tidal concentration of gas X, and VG1 is the flow rate of the source gas,
3. The method of claim 1 wherein said gas X is a gas consumed by the patient, and the
concentration of said gas X ( FG1X ) is set according to FG1X = F1ETX + -^ — γ , where
VX is the patient's minute consumption of gas X, FTETX is the target end tidal concentration of gas. X and VG1 is the flow rate of the source gas.
4. A method of simultaneously inducing target end tidal concentrations of a plurality of gases in patient, where said target end tidal concentrations are independent of each other, comprising: a) setting the source gas flow into a partial rebreathing circuit at a rate .equal to or less than the patient's minute ventilation b) setting the concentration of each gas in the source gas to attain the target end tidal concentration of that gas c) delivering the source gas to the patient through said circuit
5. The method of claim 4 wherein at least one of the gases X whose end tidal concentration is being induced, is a gas produced by the patient, and the concentration VX of said gas X in the source gas is set according to FG1X = FxETX - -7 — 7- , where VX
VG is the patient's minute production of gas X5 FTETX is the target end tidal concentration of gas X and G1 is the flow rate of the source gas.
6. The method of claim 4 wherein at least one of the gases X whose end tidal concentration is being induced, is a gas consumed by the patient, and the
VX concentration said gas X is set according to FG X = FETX + -. — 7- , where VX is the
patient's minute consumption of gas X5 FTETX is the target end tidal concentration of gas X5 and VG1 is the flow rate of the source gas.
7. A method of changing an end tidal concentration of a gas X in a patient comprising: a) setting the source gas flow into a partial rebreathing circuit at a rate equal to or less than the patient's minute ventilation b) providing a first concentration of said gas X in the source gas and delivering the source gas to the patient through said circuit in order to effect a first end tidal concentration of said gas X c) providing a second concentration of said gas X in the source gas and delivering the source gas to the patient through said circuit in order to effect a second end tidal concentration of said gas X
8. A method of changing between target end tidal concentrations of a first gas X in a patient comprising inducing the first target end tidal concentration using any of the methods of Claim 1- 7, then inducing the second target end tidal concentration using any of the methods of Claim 1- 7.
9. The method of Claim 8 further comprising keeping end tidal concentration of a second gas Y at a fixed target level using any of the methods of Claim 1- 7.
10. The method of simultaneously changing between target end tidal concentrations of two or more gases in a patient comprising inducing the first target end tidal gas concentrations using any of methods of claims 1- 7, then inducing the second target end tidal gas concentrations using any of methods of claims 1- 7.
11. The methods. of Claims 1- 10 where, for each set of target end tidal gas concentrations, the gas flow into the breathing circuit is comprised of a premixed gas
12. The methods of Claims 1- 10 where, for each set of target end tidal gas concentrations, the gas flow into the breathing circuit is comprised of a blend of at least two component gases, said component gases being blended to achieve the desired concentrations in the source gas flow of the gases whose end tidal concentrations are being targeted.
13. The method of Claims 11 or 12 where each of the component gases has a minimum safe concentration OfO2 .
14. The method of Claims 1 lor 12 where the source gas flow into the breathing circuit has a minimum safe concentration of O2 .
15. The method of Claims 13 or 14 where the minimum safe level Of O2 concentration is 10%.
16. The method of Claims 13 or 14 where the minimum safe level of O2 concentration is 10%.
17. The method of Claims 13 - 16 using 3 component gases.
18. The method of any of claims 1- 17 wherein the partial rebreathing circuit is a sequential gas delivery circuit.
19. The method of any of claims 1- 17 wherein the gas whose end tidal concentration target is being induced is O2 .
20. The method of any of claims 1- 17 wherein the gas whose end tidal concentration target is being induced is CO2 .
21. The method of Claim 17 where the component gases have the following relative concentrations: a) Gas' A: High O2 , Low CO2 b) Gas B: Low O2 , High CO2 c) Gas C: Low O2 , Low CO2
22. The method of Claim 16 where the source gases have the following concentrations: a) Gas A: 50-100% O2 , 0-20% CO2 b) Gas B: 10-30% O2 , 20-80% CO2 c) Gas C: 10-30% O2 , 0-20% CO2
23. The method of Claim 16 where the source gases have the following concentrations: a) Gas A: 100% O2 , 0% CO2 b) Gas B: 10% O2 , 20-80% CO2 c) Gas C: 10% O2 , 0% CO2
24. The method of Claim 16 where the source gases have the following concentrations: a) Gas A: 100% O2 , 0% CO2 b) Gas B: 10% O2 , 20-40% CO2 c) Gas C: 10% O2 , 0% CO2
25. The method of Claim 16 where the source gases have the following concentrations: a) Gas A: 100% O2 , 0% CO2 b) Gas B: 10% O2 , 40% CO2 c) Gas C: 10% O2 , 0% CO2
26. The method of Claim 16 where the source gases have the following concentrations: a) Gas A: 100% O2 , 0% CO2 b) Gas B: 10% O2 , 20% CO2 c) Gas C: 10% O2 , 0% CO2
27. A diagnostic method comprising any method according to claims 1 to 26.
28. A method to measure cerebrovascular reactivity comprising: a) controlling the end tidal CO2 and O2 levels of a subject using the methods of claims 20 or 21. b) monitoring a blood oxygen level dependent (BOLD) MRI signal intensity
29. The method of Claim 28 where the end tidal CO2 and O2 levels are controlled independently of each other.
30. The method of Claim 28 or 29 where the end tidal CO2 levels are changed while the end tidal O2 levels are kept constant.
31. The method of Claim 28 or 29 where the end tidal PO2 levels are changed while the end tidal PCO2 levels are kept constant
32. The method of Claim 28 or 29 where the end tidal PO2 levels and the end tidal PCO2 levels are changed simultaneously
33. A method to measure occulovascular reactivity comprising: a) controlling the end tidal CO2 and O2 levels of a subject using the methods of claims 20 or 21. b) monitoring occulovascular blood flow
34. The method of Claim 33 where the end tidal CO2 and O2 levels are controlled independently of each other.
35. The method of Claim 33 or 34 where the end tidal CO2 levels are changed while the end tidal O2 levels are kept constant.
36. The method of Claim 33 or 34 where the end tidal PO2 levels are changed while the end tidal PCO2 levels are kept constant
37. The method of Claim 33 or 34 where the end tidal PO2 levels and the end tidal PCO2 levels are changed simultaneously.
38. A method to standardize measurement of occuloVasciilar reactivity.
39. A method to measure a beneficial level of oxygenation to tissues for the purpose of radiotherapy or chemotherapy, comprising: a) controlling the end tidal CO2 and O2 levels of a subject using the methods of claims 20 or 21. b) monitoring oxygenation or blood flow in the tumor
40. The method of Claim 39 where the end tidal CO2 and O2 levels are controlled independently of each other.
41. The method of Claim 39 or 40 where the end tidal CO2 levels are changed while the • end tidal O2 levels are kept constant.
42. The method of Claim 39 or 40 where the end tidal PO2 levels are changed while the end tidal PCO2 levels are kept constant
43. The method of Claim 39 or 40 where the end tidal PO2 levels and the end tidal PCO2 levels are changed simultaneously
44. A therapeutic method comprising any method according to claims 1 to 26.
45. A therapeutic method comprising: a) using any of the methods of claims 39 to 44 to determine end tidal O2 and CO2 levels that provide a beneficial oxygenation or blood flow level to tissues for the purpose of radiotherapy or chemotherapy b) using any of the methods of claims 1 to 26 to set the end tidal O2 and CO2 levels to said levels during radiotherapy or chemotherapy
46. An apparatus for inducing target end tidal gas concentrations in a patient simultaneously, and independently of each other comprising: a) a partial rebreatbing circuit b) a source gas flow into said breathing circuit c) means for controlling the rate of said source gas flow into the circuit d) means for controlling the concentration of said gases in the source gas flow independently of each other
47. The apparatus of Claim 46 further comprising means for monitoring end tidal CO2 and O2 concentrations
48. The apparatus of Claim 46 further comprising means for monitoring pressure in the breathing circuit • ..
49. The apparatus of Claim 46 where the breathing circuit is a sequential gas delivery circuit.
50. The apparatus of Claims 46 to 49 where, for each set of target end tidal gas concentrations, the gas flow into the breathing circuit is comprised of a premixed gas
51. The apparatus of Claims 46 to 49 where, for each set of target end tidal gas concentrations, the gas flow into the breathing circuit is comprised of a blend of at least two component gases, said component gases being blended to achieve the desired concentrations in the source gas flow of the gases whose end tidal concentrations are being targeted.
52. The apparatus of Claims 46 to 51 with 3 component gases.
53. The apparatus of Claim 52 where the component gases have the following relative concentrations: a) Gas A: High O2 , Low CO2 b) Gas B: Low O2 , High CO2 c) Gas. C: Low O2 , Low CO2
54. The apparatus of Claim 53 where the component gases have the following concentrations: a) Gas A: 50-100% O2 , 0-20% CO2 b) Gas B: 10-30% O2 , 20-80% CO2 c) Gas C: 10-30% O2 , 0-20% CO2
55. The apparatus of Claim 53 where the component gases have the following concentrations: a) Gas A: 100% O2 , 0% CO2 b) Gas B: 10% O2 , 20-80% CO2 c) Gas C: 10% O2 , 0% CO2
56. The apparatus of Claim 53 where the component gases have the following concentrations: a) Gas A: 100% O2 , 0% CO2 b) Gas B: 10% O2 , 20-40% CO2 c) Gas C: 10% O2 , 0% CO2
57. The apparatus of Claim 53 where.the component gases have the following concentrations: a) Gas A: 100% O2 , 0% CO2 b) Gas B: 10% O2 , 40% CO2 c) Gas C: 10% O2 , 0% CO2
58. The apparatus of Claim 53 where the source gases have the following concentrations: a) Gas A: 100% O2 , 0% CO2 b) Gas B: 10% O2 , 20% CO2 c) Gas C: 10% O2 , 0% CO2
59. The method of claims 1 to 45 further comprising the steps of: a) monitoring the end tidal gas concentration of the patient for a particular gas b) increasing or decreasing the concentration of said gas so as to decrease the difference between the patient's end tidal concentration of said gas and the target end tidal concentration of said gas.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2005/001166 WO2007012170A1 (en) | 2005-07-28 | 2005-07-28 | A new method and apparatus to attain and maintain target end tidal gas concentrations |
PCT/CA2006/001258 WO2007012197A1 (en) | 2005-07-28 | 2006-07-28 | A method and apparatus to attain and maintain target end tidal gas concentrations |
JP2008523091A JP5415070B2 (en) | 2005-07-28 | 2006-07-28 | Method and apparatus for achieving and maintaining target end-tidal concentrations |
US11/997,100 US8459258B2 (en) | 2005-07-28 | 2006-07-28 | Method and apparatus to attain and maintain target end tidal gas concentrations |
EP06775056A EP1912694A4 (en) | 2005-07-28 | 2006-07-28 | A method and apparatus to attain and maintain target end tidal gas concentrations |
CA002616883A CA2616883A1 (en) | 2005-07-28 | 2006-07-28 | A method and apparatus to attain and maintain target end tidal gas concentrations |
US13/914,324 US20130340756A1 (en) | 2005-07-28 | 2013-06-10 | Method and apparatus to attain and maintain target end tidal gas concentrations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2005/001166 WO2007012170A1 (en) | 2005-07-28 | 2005-07-28 | A new method and apparatus to attain and maintain target end tidal gas concentrations |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007012170A1 true WO2007012170A1 (en) | 2007-02-01 |
Family
ID=37682945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2005/001166 WO2007012170A1 (en) | 2005-07-28 | 2005-07-28 | A new method and apparatus to attain and maintain target end tidal gas concentrations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007012170A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007122406A1 (en) * | 2006-04-21 | 2007-11-01 | Imperial Innovations Limited | Method and device for stabilising disordered breathing |
FR2985191A1 (en) * | 2012-01-03 | 2013-07-05 | Air Liquide | LOOP CIRCUIT GAS DISTRIBUTION DEVICE AND BUFFER RESERVOIR |
WO2017130062A1 (en) | 2016-01-27 | 2017-08-03 | Advanced Inhalation Therapies (Ait) Ltd. | Systems for inhalation of theraupeutic and diagnostic gas and methods of use thereof |
US10850052B2 (en) | 2011-12-05 | 2020-12-01 | Thornhill Scientific Inc. | Apparatus to attain and maintain target end tidal partial pressure of a gas |
US11324954B2 (en) | 2019-06-28 | 2022-05-10 | Covidien Lp | Achieving smooth breathing by modified bilateral phrenic nerve pacing |
KR102707162B1 (en) | 2016-01-27 | 2024-09-19 | 비욘드 에어 리미티드 | Inhalation system for therapeutic and diagnostic gases and method of using the same |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320093A (en) * | 1990-12-21 | 1994-06-14 | Brigham And Women's Hospital | Rapid anesthesia emergence system using closed-loop PCO2 control |
US5647345A (en) * | 1992-05-12 | 1997-07-15 | Saul; Gilbert D. | Respiratory stimulator & methods of use |
US5957129A (en) * | 1997-07-30 | 1999-09-28 | Ohmeda Inc. | On-line fault detection and correction in anesthesia delivery system |
CA2269890A1 (en) * | 1999-04-26 | 2000-10-26 | Stephen A. Carter | Device for treatment of carbon monoxide poisoning |
US20020185129A1 (en) * | 2001-05-04 | 2002-12-12 | Joseph Fisher | Method of maintaining constant arterial PCO2 and measurement of anatomic and alveolar dead space |
US6536429B1 (en) * | 1995-09-20 | 2003-03-25 | Panina Elena Vladimirovna | Method of producing a breathing mixture and an apparatus for applying the method |
WO2003092776A2 (en) * | 2002-05-01 | 2003-11-13 | Air Products And Chemicals, Inc. | Medical gas recirculation system |
WO2004073482A2 (en) * | 2003-02-19 | 2004-09-02 | Joseph Fisher | Method of measuring cardiac related parameters non-invasively via the lung during spontaneous and controlled ventilation |
-
2005
- 2005-07-28 WO PCT/CA2005/001166 patent/WO2007012170A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320093A (en) * | 1990-12-21 | 1994-06-14 | Brigham And Women's Hospital | Rapid anesthesia emergence system using closed-loop PCO2 control |
US5647345A (en) * | 1992-05-12 | 1997-07-15 | Saul; Gilbert D. | Respiratory stimulator & methods of use |
US6536429B1 (en) * | 1995-09-20 | 2003-03-25 | Panina Elena Vladimirovna | Method of producing a breathing mixture and an apparatus for applying the method |
US5957129A (en) * | 1997-07-30 | 1999-09-28 | Ohmeda Inc. | On-line fault detection and correction in anesthesia delivery system |
CA2269890A1 (en) * | 1999-04-26 | 2000-10-26 | Stephen A. Carter | Device for treatment of carbon monoxide poisoning |
US20020185129A1 (en) * | 2001-05-04 | 2002-12-12 | Joseph Fisher | Method of maintaining constant arterial PCO2 and measurement of anatomic and alveolar dead space |
WO2003092776A2 (en) * | 2002-05-01 | 2003-11-13 | Air Products And Chemicals, Inc. | Medical gas recirculation system |
WO2004073482A2 (en) * | 2003-02-19 | 2004-09-02 | Joseph Fisher | Method of measuring cardiac related parameters non-invasively via the lung during spontaneous and controlled ventilation |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007122406A1 (en) * | 2006-04-21 | 2007-11-01 | Imperial Innovations Limited | Method and device for stabilising disordered breathing |
US10850052B2 (en) | 2011-12-05 | 2020-12-01 | Thornhill Scientific Inc. | Apparatus to attain and maintain target end tidal partial pressure of a gas |
FR2985191A1 (en) * | 2012-01-03 | 2013-07-05 | Air Liquide | LOOP CIRCUIT GAS DISTRIBUTION DEVICE AND BUFFER RESERVOIR |
WO2013102707A1 (en) * | 2012-01-03 | 2013-07-11 | L'air Liquide,Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Gas distribution device with a loop circuit and buffer tank |
JP2021181026A (en) * | 2016-01-27 | 2021-11-25 | アドバンスド インハレイション セラピーズ (エイアイティー) リミテッド | Therapeutic gas and diagnostic gas inhaling system and use method thereof |
EP3407949A4 (en) * | 2016-01-27 | 2019-09-25 | Advanced Inhalation Therapies (AIT) Ltd. | Systems for inhalation of theraupeutic and diagnostic gas and methods of use thereof |
JP2019509084A (en) * | 2016-01-27 | 2019-04-04 | アドバンスド インハレイション セラピーズ (エイアイティー) リミテッド | Therapeutic and diagnostic gas inhalation systems and methods of use thereof |
AU2017212848B2 (en) * | 2016-01-27 | 2021-08-05 | Beyond Air Ltd | Systems for inhalation of therapeutic and diagnostic gas and methods of use thereof |
WO2017130062A1 (en) | 2016-01-27 | 2017-08-03 | Advanced Inhalation Therapies (Ait) Ltd. | Systems for inhalation of theraupeutic and diagnostic gas and methods of use thereof |
EP3936178A1 (en) * | 2016-01-27 | 2022-01-12 | Advanced Inhalation Therapies (AIT) Ltd. | Systems for inhalation of theraupeutic |
US11452827B2 (en) | 2016-01-27 | 2022-09-27 | Beyond Air Ltd | Systems for inhalation of therapeutic and diagnostic gas and methods of use thereof |
AU2021232787B2 (en) * | 2016-01-27 | 2023-04-20 | Beyond Air Ltd | Systems for inhalation of therapeutic and diagnostic gas and methods of use thereof |
US12029847B2 (en) | 2016-01-27 | 2024-07-09 | Beyond Air Ltd | Systems for inhalation of therapeutic and diagnostic gas and methods of use thereof |
KR102707162B1 (en) | 2016-01-27 | 2024-09-19 | 비욘드 에어 리미티드 | Inhalation system for therapeutic and diagnostic gases and method of using the same |
US11324954B2 (en) | 2019-06-28 | 2022-05-10 | Covidien Lp | Achieving smooth breathing by modified bilateral phrenic nerve pacing |
US12036409B2 (en) | 2019-06-28 | 2024-07-16 | Covidien Lp | Achieving smooth breathing by modified bilateral phrenic nerve pacing |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8459258B2 (en) | Method and apparatus to attain and maintain target end tidal gas concentrations | |
US11179044B2 (en) | Method of measuring cardiac related parameters non-invasively via the lung during spontaneous and controlled ventilation | |
EP0973572B1 (en) | Device for elimination of vapour anaesthetics from patients after surgical procedures | |
US10449311B2 (en) | Controlling arterial blood gas concentration | |
Grant et al. | Local regulation of pulmonary blood flow and ventilation-perfusion ratios in the coatimundi | |
US20030040678A1 (en) | Method and apparatus for measuring pulmonary blood flow by pulmonary exchange of oxygen and an inert gas with the blood | |
US20150114395A1 (en) | Method and arrangement for determining a ventilation need specific for a patient | |
US20090308393A1 (en) | Medical diagnostic cart and method of use | |
EP1238631A1 (en) | A method for non-invasively determining conditions in the circulatory system of a subject | |
Somogyi et al. | Precise control of end-tidal carbon dioxide levels using sequential rebreathing circuits | |
WO2007012170A1 (en) | A new method and apparatus to attain and maintain target end tidal gas concentrations | |
US20040118402A1 (en) | Apparatus and method for use in non-invasively determining conditions in the circulatory system of a subject | |
Hughes | Review series: Lung function made easy: Assessing gas exchange | |
Jorgenson et al. | Effects of intrathoracic pressure, inhalation time, and breath hold time on lung diffusing capacity | |
Gama de Abreu et al. | Evaluation of a new device for noninvasive measurement of nonshunted pulmonary capillary blood flow in patients with acute lung injury | |
Macnaughton et al. | Measurement of carbon monoxide transfer and lung volume in ventilated subjects | |
CA2419622A1 (en) | A new method of measuring cardiac related parameters non-invasively with spontaneous and controlled ventilation | |
RU2320375C2 (en) | Controllable breathing exerciser | |
Lawson Jr | Rebreathing measurements of pulmonary diffusing capacity for CO during exercise | |
RU91765U1 (en) | BIOLOGICAL FEEDBACK RESPIRATORY SIMULATOR | |
Blumenthal et al. | Relationship between inspiratory pressure and tidal volume in the anesthetized canine | |
Johnson | Pulmonary Function Testing and Reporting in the COVID-19 Era | |
Bailey | Cardiac output using throughflow of isoflurane | |
Geisler et al. | Clinical Evaluation of a Non-Invasive Inert Cas Washout Method to Quantify Cardiopulmonary Abnormalities in Critically Ill Patients | |
Geisler et al. | puter modeling of the cardiopulmonary and body per-pulmoar tis soresa (3). fusion of gas transport determined the solution of This curren workesc e e the physiologic parameters. Mathematical analysis T |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05770556 Country of ref document: EP Kind code of ref document: A1 |